Table I.
Clinicopathological factors.
| Variables | Total (n=93) | RAS wild-type (n=44) | RAS mutation (n=49) | P-value |
|---|---|---|---|---|
| Age, years (range) | 65 (39–83) | 68.5 (46–80) | 68 (39–83) | |
| Gender | 0.101 | |||
| Male | 56 (60.2) | 30 (68.1) | 26 (53.0) | |
| Female | 37 (39.8) | 14 (31.9) | 23 (47.0) | |
| Performance status, n (%) | 0.402 | |||
| 0–1 | 76 (81.1) | 35 (79.5) | 41 (83.7) | |
| 2 | 17 (19.9) | 9 (20.1) | 8 (16.3) | |
| Tumour-related symptoms, n (%) | ||||
| Weight loss >10% | 17 (18.3) | 10 (22.7) | 7 (17.0) | 0.143 |
| Bleeding | 30 (32.3) | 16 (47.0) | 7 (17.0) | 0.184 |
| Occlussion | 8 (8.6) | 1 (3.0) | 14 (34.1) | 0.056 |
| Surgery of primary tumour, n (%) | ||||
| Yes | 49 (52.6) | 18 (41.0) | 16 (32.6) | 0.019a |
| No | 42 (47.4) | 26 (59.0) | 33 (67.3) | |
| Location of metastases, n (%) | ||||
| Liver | 75 (80.6) | 38 (86.3) | 37 (75.5) | 0.145 |
| Peritoneum | 19 (20.4) | 10 (22.7) | 9 (18.3) | 0.396 |
| Lung | 24 (25.8) | 7 (15.9) | 17 (34.6) | 0.033a |
| Bone | 3 (3.2) | 0 (0.0) | 3 (6.1) | 0.142 |
| Lymph node | 22 (23.7) | 10 (22.7) | 12 (24.4) | 0.519 |
| Number of metastatic locations, n (%) | ||||
| 1 | 52 (55.9) | 25 (56.8) | 27 (20.4) | 0.517 |
| ≥2 | 48 (44.1) | 19 (43.1) | 22 (44.9) | |
| Operable metastases after chemotherapy, n (%) | ||||
| Yes | 17 (19.8) | 10 (25.0) | 7 (15.2) | 0.194 |
| No | 69 (80.0) | 30 (75.0) | 39 (84.7) | |
| Serum levels, n (%) | ||||
| CEA (high) | 62 (66.7) | 30 (75.0) | 32 (76.1) | 0.552 |
| LDH (high) | 32 (52.5) | 15 (53.5) | 17 (51.5) | 0.539 |
| Haemoglobin (low) | 22 (28.6) | 10 (27.7) | 12 (29.2) | 0.544 |
| Grade of differentiation, n (%) | ||||
| 1 | 12 (12.9) | 5 (15.6) | 7 (21.2) | 0.693 |
| 2 | 43 (46.2) | 22 (68.7) | 21 (63.6) | |
| 3 | 9 (9.7) | 5 (15.6) | 4 (12.1) | |
| Chemotherapy scheme, n (%) | ||||
| FOLFOX/XELOX | 58 (62.4) | 13 (29.5) | 22 (44.8) | 0.095 |
| FOLFOX/XELOX-B | 35 (37.6) | 31 (70.5) | 27 (55.1) |
a
Statistically significant differences. CEA, carcinoembryonic antigen; LDH, lactate dehydrogenase.